Working… Menu

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03412565
Recruitment Status : Active, not recruiting
First Posted : January 26, 2018
Last Update Posted : September 10, 2021
Information provided by (Responsible Party):
Janssen Research & Development, LLC

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : August 12, 2020
Estimated Study Completion Date : June 7, 2022
Certification/Extension First Submitted : August 9, 2021